9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Urothelial Carcinoma · Urothelial Carcinoma Bladder · Urothelial Carcinoma Recurrent · Urothelial Carcinoma of the Renal Pelvis and Ureter

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Hunan Tumor Hospital, Changsha, Hunan, China
Contact: Study coordinator (Shusuan Jiang) · jiangshusuan@hnca.org.cn · +86-0731-88651900
Contact: Principal Investigator (Shusuan Jiang)
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
Contact: Study coordinator (Hongqian Guo) · gymwpi@126.com · +86-025-83016666
Contact: Principal Investigator (Hongqian GUO)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE3

Shanghai, China

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer

Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE2

Ann Arbor, United States · Philadelphia, United States

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC) · Non-small Cell Lung Cancer (NSCLC) · Esophageal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Los Angeles, United States · Grand Rapids, United States